Pathophysiology of Atherosclerosis Formation in Autoimmune Diseases: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren’s Syndrome, and Antiphospholipid Syndrome

Dwi Aryasatya Pranaja; Anita Liliana Susanti; Andri A. Rusman

doi:10.47134/phms.v3i1.556

Authors

Dwi Aryasatya Pranaja Universitas Jendral Achmad Yani
Anita Liliana Susanti Universitas Jenderal Achmad Yani
Andri A. Rusman Universitas Jenderal Achmad Yani

DOI:

https://doi.org/10.47134/phms.v3i1.556

Keywords:

Autoimmune diseases, Atherosclerosis, Chronic inflammation

Abstract

This study aimed to systematically examine the autoimmune mechanisms contributing to atherosclerosis development in patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s syndrome, and Antiphospholipid Syndrome. The focus was on identifying immunological pathways, inflammatory mediators, and vascular changes that accelerate atherosclerosis in these autoimmune conditions. A systematic scoping review was conducted following established scoping review guidelines. Peer-reviewed studies on immune-mediated processes, endothelial dysfunction, lipid changes, or cardiovascular outcomes in autoimmune diseases were sourced from PubMed, Scopus, and Web of Science, screened via electronic searches and predefined inclusion criteria. Data extraction focused on immune cell involvement, cytokine profiles, mechanisms of vascular injury, and indicators of atherosclerotic progression.The results demonstrated that chronic systemic inflammation is a central mechanism driving accelerated atherosclerosis in autoimmune diseases. Activated immune cells, particularly monocytes, macrophages, and T lymphocytes, were consistently reported to infiltrate the vascular endothelium, promoting endothelial dysfunction and intimal thickening. Pro-inflammatory cytokines such as tumor necrosis factor-alpha and interferon-gamma were frequently associated with increased expression of adhesion molecules, oxidative stress, and foam cell formation. Altered lipid metabolism, including increased levels of oxidized low-density lipoprotein, further contributed to plaque development. In Antiphospholipid Syndrome, autoantibody-mediated endothelial injury and thrombogenic processes were prominent, while immune complex deposition and complement activation were key contributors in Systemic Lupus Erythematosus. Overall, the findings indicate that immune dysregulation and persistent inflammation substantially increase cardiovascular risk in patients with autoimmune diseases, underscoring the need for targeted anti-inflammatory and immunomodulatory strategies to reduce atherosclerotic burden

References

Atehortúa, L., Rojas, M., Vásquez, G., Muñoz-Vahos, C. H., Vanegas-García, A., & Posada-Duque, R. A. (2019). Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Research & Therapy, 21(1). DOI: https://doi.org/10.1186/s13075-018-1796-4

Benacka, O., Benacka, J., Blazicek, P., Belansky, M., Payer, J., & Killinger, Z. (2017). Speckle tracking can detect subclinical myocardial dysfunction in rheumatoid arthritis patients. Bratislava Medical Journal, 118(1), 28–33. DOI: https://doi.org/10.4149/BLL_2017_006

Benagiano, M., Borghi, M. O., Romagnoli, J., Mahler, M., Bella, C. D., & Grassi, A. (2019). Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 104(12), 2519–2527. DOI: https://doi.org/10.3324/haematol.2018.209536

Bolla, E., Tentolouris, N., Sfikakis, P. P., & Tektonidou, M. G. (2023). Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus. Frontiers in Immunology, 13. DOI: https://doi.org/10.3389/fimmu.2022.1077166

Cooksey, R., Brophy, S., Kennedy, J., Gutierrez, F. F., Pickles, T., & Davies, R. (2018). Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Seminars in Arthritis and Rheumatism, 48(3), 367–373. DOI: https://doi.org/10.1016/j.semarthrit.2018.03.005

Dalbeni, A., Giollo, A., Bevilacqua, M., Cioffi, G., Tagetti, A., & Cattazzo, F. (2020). Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients. Hypertension Research, 43(9), 922–928. DOI: https://doi.org/10.1038/s41440-020-0441-1

DeMizio, L. B., & Geraldino-Pardilla, D. J. (2020). Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. 7, 19–33. DOI: https://doi.org/10.1007/s40744-019-00189-0

Dimitroulas, T., Hodson, J., Sandoo, A., Smith, J., & Kitas, G. D. (2017). Endothelial injury in rheumatoid arthritis: A crosstalk between dimethylarginines and systemic inflammation. Arthritis Research & Therapy, 19(1). DOI: https://doi.org/10.1186/s13075-017-1232-1

Fomicheva, O. A., Popkova, T. V., Krougly, L. B., Gerasimova, E. V., Novikova, D. S., & Pogorelova, O. A. (2021). Factors of progression and occurrence of atherosclerosis in rheumatoid arthritis. Kardiologiya, 61(1), 12–21. DOI: https://doi.org/10.18087/cardio.2021.1.n1331

Giles, J. T., Reinholdt, J., Andrade, F., & Konig, M. F. (2021). Associations of antibodies targeting periodontal pathogens with subclinical coronary, carotid, and peripheral arterial atherosclerosis in rheumatoid arthritis. Arthritis & Rheumatology, 73(4), 568–575. DOI: https://doi.org/10.1002/art.41572

Gómez-Bernal, F., Quevedo-Abeledo, J. C., García-González, M., Fernández-Cladera, Y., González-Rivero, A. F., & Martín-González, C. (2023). Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus. Arthritis Research & Therapy, 25(1). DOI: https://doi.org/10.1186/s13075-023-03046-2

González-Sierra, M., Quevedo-Rodríguez, A., Romo-Cordero, A., González-Chretien, G., Quevedo-Abeledo, J. C., & de Vera-González, A. (2023). Relationship of blood inflammatory composite markers with cardiovascular risk factors and subclinical atherosclerosis in patients with rheumatoid arthritis. Life, 13(7). DOI: https://doi.org/10.3390/life13071469

Hannawi, S., Hannawi, H., & Al Salmi, I. (2020). Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis. Hypertension Research, 43, 982–984. DOI: https://doi.org/10.1038/s41440-020-0483-4

Huang, C., Ding, Y., Chen, Z., Wu, L., Wei, W., & Zhao, C. (2025). Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes. BMC Medicine, 23(1). DOI: https://doi.org/10.1186/s12916-024-03843-9

Kasher, M., Freidin, M. B., Williams, F. M. K., Cherny, S. S., Ashkenazi, S., & Livshits, G. (2024). Glycoprotein Acetyls is a novel biomarker predicting cardiovascular complications in rheumatoid arthritis. International Journal of Molecular Sciences, 25(11). DOI: https://doi.org/10.3390/ijms25115981

Kay, S. D., Poulsen, M. K., Diederichsen, A. C. P., & Voss, A. (2016). Coronary, carotid, and lower-extremity atherosclerosis and their interrelationship in Danish patients with systemic lupus erythematosus. Journal of Rheumatology, 43(2), 315–322. DOI: https://doi.org/10.3899/jrheum.150488

Kolitz, T., Shiber, S., Sharabi, I., Winder, A., & Zandman-Goddard, G. (2019). Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Frontiers in Immunology, 10. DOI: https://doi.org/10.3389/fimmu.2019.00941

Liu, S., Li, X., Yang, Q., Wang, N., Xu, J., & Li, L. (2023). Association between atherosclerosis and primary Sjogren’s syndrome: A cross-sectional study. Health Science Reports, 6(10). DOI: https://doi.org/10.1002/hsr2.1638

Liu, T., Shi, N., Zhang, S., Silverman, G. J., & Duan, X. W. (2020). Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. Lupus, 29(3), 273–282. DOI: https://doi.org/10.1177/0961203320904779

Lopez-Pedrera, C., Barbarroja, N., Patiño-Trives, A. M., Collantes, E., Aguirre, M. A., & Perez-Sanchez, C. (2019). New biomarkers for atherothrombosis in antiphospholipid syndrome: Genomics and epigenetics approaches. Frontiers in Immunology, 10. DOI: https://doi.org/10.3389/fimmu.2019.00764

Mahmoudi, M., Aslani, S., Fadaei, R., & Jamshidi, A. R. (2017). New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. International Journal of Rheumatic Diseases, 20, 287–297. DOI: https://doi.org/10.1111/1756-185X.12999

Park, J. K., Kim, J. Y., Moon, J. Y., Ahn, E. Y., Lee, E. Y., & Lee, E. B. (2016). Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress. Arthritis Research & Therapy, 18(1). DOI: https://doi.org/10.1186/s13075-016-1204-x

Popescu, D., Rezus, E., Badescu, M. C., Dima, N., & Dragoi, I. T. (2023). Cardiovascular risk assessment in rheumatoid arthritis: Accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life, 13. DOI: https://doi.org/10.3390/life13020319

Qi, X., Huang, Q., Wang, S., Qiu, L., Chen, X., & Ouyang, K. (2023). Identification of the shared mechanisms and common biomarkers between Sjögren’s syndrome and atherosclerosis using integrated bioinformatics analysis. Frontiers in Medicine, 10. DOI: https://doi.org/10.3389/fmed.2023.1185303

Romo-Cordero, A., González-Sierra, M., Quevedo-Abeledo, J. C., Quevedo-Rodríguez, A., Gómez-Bernal, F., & de Vera-González, A. (2023). The ratio of monocytes to HDL-cholesterol is associated with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis. Life, 13(10). DOI: https://doi.org/10.3390/life13101995

Tselios, K., Gladman, D. D., Su, J., Ace, O., & Urowitz, M. B. (2017). Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: A long-term prospective study. Journal of Rheumatology, 44(12), 1841–1849. DOI: https://doi.org/10.3899/jrheum.161121

Urowitz, M. B., Su, J., & Gladman, D. D. (2020). Atherosclerotic vascular events in systemic lupus erythematosus: An evolving story. Journal of Rheumatology, 47(1), 66–71. DOI: https://doi.org/10.3899/jrheum.180986

Weber, B. N., Giles, J. T., & Liao, K. P. (2023). Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nature Reviews Rheumatology, 19, 417–428. DOI: https://doi.org/10.1038/s41584-023-00969-7

Weijers, J. M., Semb, A. G., Rollefstad, S., Kitas, G. D., & van Riel, P. L. C. M. (2020). Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis. Rheumatology International, 40(4), 523–527. DOI: https://doi.org/10.1007/s00296-020-04533-4

Yennemadi, A. S., Jordan, N., Diong, S., Keane, J., & Leisching, G. (2024). The link between dysregulated immunometabolism and vascular damage: Implications for the development of atherosclerosis in systemic lupus erythematosus and other rheumatic diseases. Journal of Rheumatology, 51, 234–241. DOI: https://doi.org/10.3899/jrheum.2023-0833

Zegkos, T., Kitas, G., & Dimitroulas, T. (2016). Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Therapeutic Advances in Musculoskeletal Disease, 8, 86–101. DOI: https://doi.org/10.1177/1759720X16643340